We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Biocartis SA

Biocartis is a commercial stage molecular diagnostics company that develops diagnostics technology platforms for mult... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Rapid CE-Marked IVD Lung Cancer Test Delivers Results Within Three Hours

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: CE-marked IVD Idylla GeneFusion Panel is intended for fast treatment decisions in lung cancer (Photo courtesy of Biocartis)
Image: CE-marked IVD Idylla GeneFusion Panel is intended for fast treatment decisions in lung cancer (Photo courtesy of Biocartis)

Lung cancer remains the leading cause of cancer deaths, with non-small cell lung cancer (NSCLC) being the most common type of lung cancer. Gene fusions represent an important class of gene rearrangements and have become important in NSCLC, as they are linked to responses to certain targeted therapies. Their accurate and fast detection is critical to guide therapy choices, which is the reason why testing for gene rearrangements such as gene fusions is included in international NSCLC testing guidelines. However, comprehensive testing of actionable gene rearrangements in NSCLC is often complex and can require different technologies. In order to test all needed biomarkers, laboratories usually have to use different instruments which are often not available within their own lab. Using different instruments also requires having enough biopsy samples of sufficient good quality, which can be difficult to obtain, especially in NSCLC patients. Now, a rapid CE-marked IVD lung cancer testing solution for laboratories provides comprehensive testing results within 180 minutes, significantly faster than currently available testing methods which often take days or even weeks before results are available.

The fully automated Idylla GeneFusion Panel (CE-IVD) from Biocartis Group NV (Mechelen, Belgium) detects in one single cartridge ALK, ROS1, RET and METex14 skipping, a wide range of actionable targets relevant in NSCLC. Designed for use in clinical laboratories, the panel consolidates traditional testing workflows into one streamlined, fully-automated process. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. However, the panel only requires a limited amount of sample, thereby saving valuable tissue specimens.

The Idylla GeneFusion Panel detects ALK, ROS1 and RET fusions & MET exon 14 skipping in a single cartridge using only 1-3 FFPE tissue sections from patients with NSCLC. By offering results in a minimum amount of time, the panel shortens the time from sample to treatment initiation to one or two days. The panel demonstrated high concordance results in a clinical comparison study where ALK was compared with IHC, and ROS1, RET and METex14 skipping were compared with NGS.

“Turnaround time and time-to-treatment remains an important barrier to molecular testing. It has been demonstrated that 10% to 20% of advanced lung cancer patients do not receive the appropriate targeted therapy because biomarker results are not provided in a timely fashion,” said Herman Verrelst, Chief Executive Officer of Biocartis.

Related Links:
Biocartis Group NV 

New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Silver Supplier
CLIA Microwell Strip Luminometer
LumiStat 4900
New
Silver Supplier
Urea Breath Test
13C-Urea Breath Test
New
POC BNP Fluorescence Immunoassay
Quidel Triage BNP Test

Print article

Channels

Industry

view channel
Image: The Accelerate Arc Module & BC kit is registered as an IVD (Photo courtesy of Accelerate Diagnostics)

BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.